Washington, D.C. 20549






Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2019



MeiraGTx Holdings plc

(Exact name of registrant as specified in its charter)




Cayman Islands   001-38520   Not applicable

(State or other jurisdiction of

incorporation or organization)



File Number)


(I.R.S. Employer

Identification No.)

450 East 29th Street, 15th Floor

New York, NY 10016

(Address of principal executive offices) (Zip code)

(646) 860-7985

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Ordinary Shares, $0.00003881 par value per share   MGTX   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 2.02.

Results of Operations and Financial Condition.

On November 7, 2019 MeiraGTx Holdings plc (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2019. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.



99.1    Press release of MeiraGTx Holdings plc, dated November 7, 2019.




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2019



/s/ Richard Giroux

Name:   Richard Giroux
Title:   Chief Financial Officer and Chief
Operating Officer




Exhibit 99.1



MeiraGTx Reports Third Quarter 2019 Financial Results

LONDON and NEW YORK, November 7, 2019 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the quarter ended September 30, 2019 and provided an update on recent progress.

“Over the course of the third quarter, we continued to advance our broad pipeline of investigational gene therapies,” said Alexandria Forbes, Ph.D., president and CEO, MeiraGTx. “In recent months, we have shared data from our first completed clinical trial with the medical community at the annual meetings of the Retina Society and the American Academy of Ophthalmology. Additionally, we continue to make strategic investments to develop next-generation, best-in-class gene therapy technologies, including our recent initiative to build a second cGMP manufacturing facility and to bring plasmid production in house.”

Third Quarter 2019 Clinical Development Highlights

Phase 1/2 trial of AAV-RPE65 for RPE65-Associated Retinal Dystrophy: Data from the trial were presented in September 2019 at the 52nd Annual Scientific Meeting of the Retina Society and in October 2019 at the American Academy of Ophthalmology Annual Meeting. These data demonstrated that AAV-RPE65 improved functional vision, as assessed by vision-guided mobility maze, retinal function, as assessed by static perimetry, and several measures of central vision, including central retinal sensitivity, visual acuity and contrast sensitivity.

Phase 1/2 AQUAx trial of AAV-AQP1 for Grade 2/3 Radiation-Induced Xerostomia: MeiraGTx initiated the open-label, multi-center, dose-finding Phase 1/2 trial in the third quarter of 2019 and is enrolling patients with radiation-induced Grade 2/3 xerostomia following treatment for head and neck cancer.

The Company’s single center Phase 1 dose-finding study of AAV-AQP1 also continues to enroll patients at the National Institutes of Health (NIH). Enrollment in the third dose escalation cohort was completed in the third quarter of 2019.

Janssen-partnered investigational gene therapies: MeiraGTx and Janssen Pharmaceuticals, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, continue to advance a portfolio of partnered gene therapies for the treatment of inherited retinal diseases, including the Company’s ongoing Phase 1/2 studies of AAV-RPGR for X-linked retinitis pigmentosa (XLRP) and AAV-CNGB3 and AAV-CNGA3 for achromatopsia (ACHM).



For more information related to all of our clinical trials, please visit www.clinicaltrials.gov.

Third Quarter 2019 Corporate Highlights

Expanding manufacturing capabilities: In August 2019, MeiraGTx raised approximately $75 million of gross proceeds in a public offering of approximately 3.2 million of its ordinary shares. The Company intends to use a portion of the proceeds of this offering to expand its manufacturing capabilities, including building a second cGMP viral vector manufacturing facility as well as a cGMP plasmid production facility. MeiraGTx is completing feasibility studies for the second facility and expects to begin construction in 2020.

Third Quarter 2019 Financial Results

As of September 30, 2019, MeiraGTx had cash and cash equivalents of approximately $253.3 million. This capital will be sufficient to fund its operating expenses and capital expenditure requirements into 2022.

Comparison of Three Months Ended September 30, 2019 and 2018

General and administrative expenses were $9.9 million for the three months ended September 30, 2019, compared to $6.6 million for the three months ended September 30, 2018. The increase of $3.3 million was primarily due to increases in payroll, insurance and rent expenses, consulting fees and share-based compensation.

Research and development expenses for the three months ended September 30, 2019 were $4.6 million, compared to $8.1 million for the three months ended September 30, 2018. The decrease of $3.5 million was primarily due to an increase in research funding provided by our license and collaboration agreements with Janssen, which was partially offset by increases in costs related to our clinical trials and to the manufacture of material for our clinical trials.

Foreign currency gain was $0.1 million for the three months ended September 30, 2019 compared to a loss of $0.7 million for the three months ended September 30, 2018. The increase of $0.8 million was primarily due to a strengthening of the U.S. dollar against the pound sterling during the three months ended September 30, 2019.

Net loss for the three months ended September 30, 2019 was $10.5 million, or $(0.30) basic and diluted net loss per ordinary share, compared to a net loss of $15.4 million, or $(0.59) basic and diluted net loss per ordinary share for the three months ended September 30, 2018.

MeiraGTx ended the third quarter of 2019 with $253.3 million in cash and cash equivalents, compared to $88.5 million as of September 30, 2018.



About MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia and xerophthalmia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit www.meiragtx.com.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our product candidate development and anticipated 2019 milestones regarding our pre-clinical and clinical data and reporting of such data and the timing of results of data in connection with AAV-AQP1 for the treatment of patients with radiation-induced Grade 2/3 xerostomia, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, our incurrence of significant losses; any inability to achieve or maintain profitability, acquire additional capital, identify additional and develop existing product candidates, successfully execute strategic priorities, bring product candidates to market, expansion of our manufacturing facilities and processes, successfully enroll patients in and complete clinical trials, accurately predict growth assumptions, recognize benefits of any orphan drug designations, retain key personnel or attract qualified employees, or incur expected levels of operating expenses; failure of early data to predict eventual outcomes; failure to obtain FDA or other regulatory approval for product candidates within expected time frames or at all; the novel nature and impact of negative public opinion of gene therapy; failure to comply with ongoing regulatory obligations; contamination or shortage of raw materials; changes in healthcare laws; risks associated with our international operations; significant competition in the pharmaceutical and biotechnology industries; dependence on third parties; risks related to intellectual property; litigation risks; and the other important factors discussed under the caption “Risk Factors” in our Quarterly



Report on Form 10-Q for the quarterly period ended September 30, 2019, as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.




Elizabeth Broder

(646) 860-7983




W2O pure

Christiana Pascale

(212) 257-6722







     September 30,     December 31,  
     2019     2018  




Cash and cash equivalents

   $ 253,330,623     $ 68,080,175  

Prepaid expenses

     6,248,981       1,937,785  

Other current assets

     11,509,144       4,634,105  







Total Current Assets

     271,088,748       74,652,065  

Right-of-use assets

     28,801,757       —    

Property and equipment, net

     16,899,147       22,014,237  

Security deposits

     839,149       105,085  

Restricted cash

     123,376       123,376  








   $ 317,752,177     $ 96,894,763  










Accounts payable

   $ 3,798,441     $ 3,042,861  

Accrued expenses

     9,346,895       11,991,697  

Lease obligations, current

     2,028,689       27,199  

Deferred revenue - related party, current

     24,115,777       —    

Other current liabilities

     —         437,053  







Total Current Liabilities

     39,289,802       15,498,810  

Deferred revenue - related party

     62,837,715       —    

Lease obligations

     20,600,077       7,097  

Deferred rent

     —         201,264  

Asset retirement obligations

     131,213       128,119  








     122,858,807       15,835,290  











Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized 36,571,722 issued and outstanding at September 30, 2019 27,386,632 issued and outstanding at December 31, 2018

     1,420       1,064  

Capital in excess of par value

     390,053,479       229,054,460  

Accumulated other comprehensive income

     2,393,372       293,666  

Accumulated deficit

     (197,554,901     (148,289,717







Total Shareholders’ Equity

     194,893,370       81,059,473  








   $ 317,752,177     $ 96,894,763  













     For the Three-Month Period Ended
September 30,
    For the Nine-Month Period Ended
September 30,
     2019     2018     2019     2018  

License revenue - related party

   $ 3,582,586     $ —       $ 6,349,222     $ —    













Operating expenses:


General and administrative

   $ 9,874,810     $ 6,629,052     $ 31,811,456     $ 35,129,120  

Research and development

     4,614,446       8,109,160       27,362,432       22,827,176  













Total operating expenses

     14,489,256       14,738,212       59,173,888       57,956,296  













Loss from operations

     (10,906,670     (14,738,212     (52,824,666     (57,956,296

Other non-operating income (expense):


Foreign currency gain (loss)

     115,470       (677,488     3,117,047       (2,425,488

Change in fair value of warrant liability

     —         —         —         (1,514,775

Other income

     —         —         —         83,075  

Interest income

     959       264       40,686       50,926  

Interest expense

     (9,283     (9,508     (28,311     (46,571













Loss before income taxes

     (10,799,524     (15,424,944     (49,695,244     (61,809,129

Benefit for income taxes

     338,670       —         430,060       —    













Net loss

     (10,460,854     (15,424,944     (49,265,184     (61,809,129

Other comprehensive income:


Foreign currency translation, net of tax of $338,670 and $0 for the three-month periods ended September 30, 2019 and 2018, respectively and $430,060 and $0 for the nine-month periods ended September 30, 2019 and 2018, respectively

     1,653,507       508,758       2,099,706       1,730,000  













Total comprehensive loss

   $ (8,807,347   $ (14,916,186   $ (47,165,478   $ (60,079,129













Net loss

   $ (10,460,854   $ (15,424,944   $ (49,265,184   $ (61,809,129

Accretion on convertible preferred C shares and warrants

     —         —         —         (1,806,512













Adjusted net loss

   $ (10,460,854   $ (15,424,944   $ (49,265,184   $ (63,615,641













Basic and diluted adjusted net loss per ordinary share

   $ (0.30   $ (0.59   $ (1.53   $ (3.89













Weighted-average number of ordinary shares outstanding

     34,663,623       26,340,450       32,111,733       16,355,849